Experts discuss the evolving use of immune checkpoint inhibition in patients with advanced HCC.
This activity is intended for oncologists, gastroenterologists, and hepatologists.
The goal of this activity is to discuss the emerging role of immunotherapy in patients with unresectable hepatocellular carcinoma (HCC).
Approximate Time to Complete: 30 minutes
Credit Available: Jan. 25, 2019- Jan. 25, 2020
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
- Have increased knowledge emerging clinical data on the use of immune checkpoint inhibitor regimens in patients with unresectable HCC across the spectrum of disease
- Have greater competence related identifying appropriate candidates for immune checkpoint inhibition among patients with unresectable HCC